Lumos Pharma, Inc. (LUMO)
- Previous Close
2.8000 - Open
2.7436 - Bid --
- Ask 2.8700 x 100
- Day's Range
2.7436 - 2.7700 - 52 Week Range
2.4100 - 4.5500 - Volume
681 - Avg. Volume
20,087 - Market Cap (intraday)
22.483M - Beta (5Y Monthly) 0.35
- PE Ratio (TTM)
-- - EPS (TTM)
-4.1800 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.50
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.
lumos-pharma.comRecent News: LUMO
Performance Overview: LUMO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LUMO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LUMO
Valuation Measures
Market Cap
22.40M
Enterprise Value
-13.09M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.96
Price/Book (mrq)
0.82
Enterprise Value/Revenue
-6.38
Enterprise Value/EBITDA
0.36
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-40.53%
Return on Equity (ttm)
-78.34%
Revenue (ttm)
2.05M
Net Income Avi to Common (ttm)
-34.03M
Diluted EPS (ttm)
-4.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
36.08M
Total Debt/Equity (mrq)
2.14%
Levered Free Cash Flow (ttm)
-19.55M